

**Consolidated Financial Results for FY2016**

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2015		FY2016		YoY
	Apr. 2015-Mar. 2016		Apr. 2016-Mar. 2017		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	43,215	100.0%	48,527	100.0%	112.3%
Cost of Sales	26,072	60.3%	29,614	61.0%	113.6%
Gross Profit	17,143	39.7%	18,913	39.0%	110.3%
Selling, General and Administrative Expenses	15,861	36.7%	17,119	35.3%	107.9%
Operating Income	1,283	3.0%	1,793	3.7%	139.8%
Profit Attributable to Owners of Parent	701	1.6%	2,944	6.1%	420.0%

**Forecast of Consolidated Financial Results for the FY2017**

	FY2016 Actual		FY2017 Forecast	
	Apr. 2016-Mar. 2017		Apr. 2017-Mar. 2018	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	48,527	100.0%	50,000	100.0%
Operating Income	1,793	3.7%	2,000	4.0%
Profit Attributable to Owners of Parent	2,944	6.1%	1,800	3.6%

**Sales of Main Products**

(Billions of yen)

Therapeutic Category	Products	FY2015 Actual	FY2016 Actual	FY2017 Forecast
Antihypertensive agent	CANDESARTAN*	9.11	12.75	13.64
Thyroid hormone	THYRADIN	4.78	5.45	5.50
Hyperlipidemic agent	LIPDIL	4.46	4.41	4.32
LH-RH derivative	LEUPRORELIN	2.72	3.84	3.95
Prostate cancer therapeutic agent	BICALUTAMIDE	1.80	1.78	1.77
Antihypertensive agent	AMLODIPINE	1.80	1.67	1.66
Emergency contraceptive	NORLEVO	0.91	1.14	1.11
Antithyroid agent	MERCAZOLE	0.50	1.14	1.11
Proton pump inhibitor	RABEPRAZOLE	1.04	0.95	0.95
Oral contraceptives	ANGE	0.96	0.93	0.91

\*Including CANDESARTAN formulation's sales